Savara Inc. Stock
Price
Target price
€3.80
€3.80
-0.520%
-0.02
-0.520%
€8.00
30.05.24 / Frankfurt
WKN: A2DQ2B / Symbol: MSTX / Name: Savara / Stock / Pharmaceuticals / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Savara Inc. Stock
Savara Inc. shows a slight decrease today, losing -€0.020 (-0.520%) compared to yesterday.
The community is currently still undecided about Savara Inc. with 1 Buy predictions and 1 Sell predictions.
Based on the current price of 3.8 € the target price of 8 € shows a potential of 110.53% for Savara Inc. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Savara Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Savara Inc. in the next few years
Pros
?
S********** s********
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
B****
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Savara Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Savara Inc. | -0.520% | 1.064% | -11.215% | 49.606% | -12.037% | 160.274% | -60.756% |
| Rockwell Medical Inc. | 1.120% | -1.333% | 19.691% | -33.646% | -6.055% | -78.600% | -96.307% |
| Avid Bioservices Inc | -0.680% | -9.877% | 2.098% | -48.951% | 19.672% | -58.046% | 113.170% |
| Gritstone Oncology Inc | -1.050% | -7.230% | -8.467% | -57.728% | -63.052% | -90.889% | - |
News
Savara to Present at the Jefferies Global Healthcare Conference
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee.
On May 14, 2024